Page 699 - Read Online

Page 12 of 12 Fung et al. Hepatoma Res 2018;4:62 I http://dx.doi.org/10.20517/2394-5079.2018.92

Cancer 2010;127:2893-917.
2. Sherman M. Hepatocellular carcinoma: epidemiology, surveillance, and diagnosis. Semin Liver Dis 2010;30:3-16.
3. Yuen MF, Hou JL, Chutaputti A; Asia Pacific Working Party on Prevention of Hepatocellular Carcinoma. Hepatocellular carcinoma in the
Asia pacific region. J Gastroenterol Hepatol 2009;24:346-53.
4. Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F, Montalto F, Ammatuna M, Morabito A, Gennari L. Liver
transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996;334:693-9.
5. Yao FY, Ferrell L, Bass NM, Watson JJ, Bacchetti P, Venook A, Ascher NL, Roberts JP. Liver transplantation for hepatocellular carcinoma:
expansion of the tumor size limits does not adversely impact survival. Hepatology 2001;33:1394-403.
6. Welker MW, Bechstein WO, Zeuzem S, Trojan J. Recurrent hepatocellular carcinoma after liver transplantation - an emerging clinical
challenge. Transpl Int 2013;26:109-18.
7. Sharma P, Welch K, Hussain H, Pelletier SJ, Fontana RJ, Marrero J, Merion RM. Incidence and risk factors of hepatocellular carcinoma
recurrence after liver transplantation in the MELD era. Dig Dis Sci 2012;57:806-12.
8. Han SH, Reddy KR, Keeffe EB, Soldevila-Pico C, Gish R, Chung RT, Degertekin B, Lok A; NIH HBV OLT Study Group. Clinical
outcomes of liver transplantation for HBV-related hepatocellular carcinoma: data from the NIH HBV OLT study. Clin Transplant
2011;25:E152-62.
9. Wu JC, Huang YH, Chau GY, Su CW, Lai CR, Lee PC, Huo TI, Sheen IJ, Lee SD, Lui WY. Risk factors for early and late recurrence in
hepatitis B-related hepatocellular carcinoma. J Hepatol 2009;51:890-7.
10. Vivarelli M, Bellusci R, Cucchetti A, Cavrini G, De Ruvo N, Aden AA, La Barba G, Brillanti S, Cavallari A. Low recurrence rate of
hepatocellular carcinoma after liver transplantation: better patient selection or lower immunosuppression? Transplantation 2002;74:1746-51.
11. Wang GY, Yang Y, Li H, Zhang J, Jiang N, Li MR, Zhu HB, Zhang Q, Chen GH. A scoring model based on neutrophil to lymphocyte ratio
predicts recurrence of HBV-associated hepatocellular carcinoma after liver transplantation. PLoS One 2011;6:e25295.
12. Shimoda M, Ghobrial RM, Carmody IC, Anselmo DM, Farmer DG, Yersiz H, Chen P, Dawson S, Durazo F, Han S, Goldstein LI, Saab S,
Hiatt J, Busuttil RW. Predictors of survival after liver transplantation for hepatocellular carcinoma associated with Hepatitis C. Liver Transpl
2004;10:1478-86.
13. Li MR, Chen GH, Cai CJ, Wang GY, Zhao H. High hepatitis B virus DNA level in serum before liver transplantation increases the risk of
hepatocellular carcinoma recurrence. Digestion 2011;84:134-41.
14. Saab S, Yeganeh M, Nguyen K, Durazo F, Han S, Yersiz H, Farmer DG, Goldstein LI, Tong MJ, Busuttil RW. Recurrence of hepatocellular
carcinoma and hepatitis B reinfection in hepatitis B surface antigen-positive patients after liver transplantation. Liver Transpl 2009;15:1525-
34.
15. Fung J, Chan SC, Yuen MF, Lai CL, Chok KSH, Sharr W, Dai WC, Fan ST, Lo CM. Long-term outcome of lamivudine mono-prophylaxis
after liver transplantation in hepatitis B patients. Hepatology 2011;54:450A.
16. Faria LC, Gigou M, Roque-Afonso AM, Sebagh M, Roche B, Fallot G, Ferrari TC, Guettier C, Dussaix E, Castaing D, Brechot C, Samuel
D. Hepatocellular carcinoma is associated with an increased risk of hepatitis B virus recurrence after liver transplantation. Gastroenterology
2008;134:1890-9.
17. Bozorgzadeh A, Orloff M, Abt P, Tsoulfas G, Younan D, Kashyap R, Jain A, Mantry P, Maliakkal B, Khorana A, Schwartz S. Survival
outcomes in liver transplantation for hepatocellular carcinoma, comparing impact of hepatitis C versus other etiology of cirrhosis. Liver
Transpl 2007;13:807-13.
18. Takeda K, Maruki M, Yamagaito T, Muramatsu M, Sakai Y, Tobimatsu H, Kobayashi H, Mizuno Y, Hamaguchi Y. Highly sensitive detection
of hepatitis B virus surface antigen by use of a semiautomated immune complex transfer chemiluminescence enzyme immunoassay. J Clin
Microbiol 2013;51:2238-44.
19. Seto WK, Tanaka Y, Wong DK, Shinkai N, Cheung KS, Liu KS, Fung J, Lai CL, Yuen MF. Longitudinal profiles of highly sensitive
hepatitis B surface antigen levels: re-evaluation of HBsAg seroclearance. Liver Int 2016;36:642-50.
20. Fung J, Lai CL, Young J, Wong DK, Yuen J, Seto WK, Yuen MF. Quantitative hepatitis B surface antigen levels in patients with chronic
hepatitis B after 2 years of entecavir treatment. Am J Gastroenterol 2011;106:1766-73.
21. Kiyici M, Yilmaz M, Akyildiz M, Arikan C, Aydin U, Sigirli D, Nart D, Yilmaz F, Ozacar T, Karasu Z, Kilic M. Association between
hepatitis B and hepatocellular carcinoma recurrence in patients undergoing liver transplantation. Transplant Proc 2008;40:1511-7.
22. Fung J, Cheung C, Chan SC, Yuen MF, Chok KS, Sharr W, Dai WC, Chan AC, Cheung TT, Tsang S, Lam B, Lai CL, Lo CM. Entecavir
monotherapy is effective in suppressing hepatitis B virus after liver transplantation. Gastroenterology 2011;141:1212-9.
23. Fung J, Chan SC, Cheung C, Yuen MF, Chok KS, Sharr W, Chan AC, Cheung TT, Seto WK, Fan ST, Lai CL, Lo CM. Oral nucleoside/
nucleotide analogs without hepatitis B immune globulin after liver transplantation for hepatitis B. Am J Gastroenterol 2013;108:942-8.
24. Lo CM, Fung JT, Lau GK, Liu CL, Cheung ST, Lai CL, Fan ST, Wong J. Development of antibody to hepatitis B surface antigen after liver
transplantation for chronic hepatitis B. Hepatology 2003;37:36-43.
25. Fung J, Lai CL, Young J, Wong DK, Yuen J, Seto WK, Yuen MF. Stability of hepatitis B surface antigen over time: implications for studies
using stored sera. J Med Virol 2011;83:1900-4.